MX2009009132A - Composiciones medicinales mejoradas que comprenden buprenorfina y naltrexona. - Google Patents

Composiciones medicinales mejoradas que comprenden buprenorfina y naltrexona.

Info

Publication number
MX2009009132A
MX2009009132A MX2009009132A MX2009009132A MX2009009132A MX 2009009132 A MX2009009132 A MX 2009009132A MX 2009009132 A MX2009009132 A MX 2009009132A MX 2009009132 A MX2009009132 A MX 2009009132A MX 2009009132 A MX2009009132 A MX 2009009132A
Authority
MX
Mexico
Prior art keywords
naltrexone
buprenorphine
medicinal compositions
improved medicinal
dosage form
Prior art date
Application number
MX2009009132A
Other languages
English (en)
Spanish (es)
Inventor
Christopher Bourne Chapleo
Neil Hyde
Original Assignee
Reckitt Benckiser Healthcare
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37965733&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009009132(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Reckitt Benckiser Healthcare filed Critical Reckitt Benckiser Healthcare
Publication of MX2009009132A publication Critical patent/MX2009009132A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MX2009009132A 2007-03-01 2008-02-15 Composiciones medicinales mejoradas que comprenden buprenorfina y naltrexona. MX2009009132A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0703966A GB2447014A (en) 2007-03-01 2007-03-01 Analgesic composition comprising a specific ratio of buprenorphine and naltrexone
PCT/GB2008/000521 WO2008104735A1 (en) 2007-03-01 2008-02-15 Improved medicinal compositions comprising buprenorphine and naltrexone

Publications (1)

Publication Number Publication Date
MX2009009132A true MX2009009132A (es) 2009-09-03

Family

ID=37965733

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009009132A MX2009009132A (es) 2007-03-01 2008-02-15 Composiciones medicinales mejoradas que comprenden buprenorfina y naltrexona.

Country Status (21)

Country Link
US (1) US8912211B2 (enExample)
EP (1) EP2125019B1 (enExample)
JP (1) JP5577101B2 (enExample)
KR (1) KR20090115861A (enExample)
CN (1) CN101622014A (enExample)
AR (1) AR065580A1 (enExample)
AU (1) AU2008220620A1 (enExample)
BR (1) BRPI0807902A2 (enExample)
CA (1) CA2678481C (enExample)
CL (1) CL2008000608A1 (enExample)
DK (1) DK2125019T3 (enExample)
ES (1) ES2475734T3 (enExample)
GB (1) GB2447014A (enExample)
HR (1) HRP20140592T1 (enExample)
MX (1) MX2009009132A (enExample)
PE (1) PE20081799A1 (enExample)
PL (1) PL2125019T3 (enExample)
PT (1) PT2125019E (enExample)
TW (1) TW200836737A (enExample)
WO (1) WO2008104735A1 (enExample)
ZA (1) ZA200905689B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9095548B2 (en) 2010-04-29 2015-08-04 Allodynic Therapeutics, Llc Combinations of opioid/TLR4 antagonists and acetyl-para-aminophenol (APAP) for use in the treatment of pain
US9205081B2 (en) 2010-04-29 2015-12-08 Allodynic Therapeutics, Llc Combinations of opiod/TLR4 antagonist and a cyclooxygenase (COX) inhibitor for use in the treatment of pain
AR083062A1 (es) * 2010-09-21 2013-01-30 Purdue Pharma Lp Analogos de buprenorfina y su uso en el tratamiento del dolor
WO2014160077A1 (en) * 2013-03-13 2014-10-02 Allodynic Therapeutics, Llc Compositions to reduce pain comprising an opioid/toll-like receptor 4 antagonist, dextro enantiomers thereof, and methods of use therefor
ES2703623T3 (es) * 2013-06-28 2019-03-11 Purdue Pharma Lp Antagonistas opioides para uso en el tratamiento de una arritmia inducida por analgésicos opioides
JP2016529328A (ja) 2013-09-10 2016-09-23 インシス・ファーマ・インコーポレーテッド 舌下ブプレノルフィンスプレー
US9918981B2 (en) 2013-09-10 2018-03-20 Insys Development Company, Inc. Liquid buprenorphine formulations
US9839611B2 (en) 2013-09-10 2017-12-12 Insys Development Company, Inc. Sublingual buprenorphine spray
US9867818B2 (en) 2013-09-10 2018-01-16 Insys Development Company, Inc. Sublingual buprenorphine spray
JP2017519803A (ja) 2014-07-08 2017-07-20 インシス・ファーマ・インコーポレーテッド 舌下ナロキソンスプレー
US10722510B2 (en) 2014-07-08 2020-07-28 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US10617686B2 (en) 2014-07-08 2020-04-14 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
WO2018081792A2 (en) 2016-10-31 2018-05-03 Allodynic Therapeutics, Llc Combinations of opioid/tlr4 antagonists and acetaminophen for use in the treatment of emotional pain and insomnia
US12343340B2 (en) 2020-12-31 2025-07-01 Soin Therapeutics Llc Methods of using low dose naltrexone to treat chronic pain
US11752143B2 (en) 2020-12-31 2023-09-12 Soin Therapeutics Llc Methods of using low dose naltrexone to treat chronic pain

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US572149A (en) * 1896-12-01 Tobacco-cutting machine
GB8430346D0 (en) 1984-11-30 1985-01-09 Reckitt & Colmann Prod Ltd Analgesic compositions
GB8728294D0 (en) 1987-12-03 1988-01-06 Reckitt & Colmann Prod Ltd Treatment compositions
US5272149A (en) * 1992-05-05 1993-12-21 Stalling Reginald W Symptom controlled receptor substitution for addiction withdrawl
US6096756A (en) * 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
AU755790B2 (en) 1997-12-22 2002-12-19 Euro-Celtique S.A. A method of preventing abuse of opioid dosage forms
AR031682A1 (es) * 1999-11-19 2003-10-01 Reckitt Benckiser Helthcare Uk Composiciones farmaceuticas
ATE431145T1 (de) * 2000-02-08 2009-05-15 Euro Celtique Sa Missbrauchssichere orale opioid-agonist zubereitungen
US20050191340A1 (en) * 2002-08-09 2005-09-01 Gruenenthal Gmbh Opioid-receptor antagonists in transdermal systems having buprenorphine

Also Published As

Publication number Publication date
CN101622014A (zh) 2010-01-06
DK2125019T3 (da) 2014-06-30
CL2008000608A1 (es) 2008-10-03
PL2125019T3 (pl) 2014-08-29
PE20081799A1 (es) 2008-12-18
CA2678481A1 (en) 2008-09-04
ES2475734T3 (es) 2014-07-11
US20100120812A1 (en) 2010-05-13
GB2447014A (en) 2008-09-03
JP2010520183A (ja) 2010-06-10
US8912211B2 (en) 2014-12-16
EP2125019B1 (en) 2014-04-09
HRP20140592T1 (hr) 2014-09-12
CA2678481C (en) 2014-11-18
EP2125019A1 (en) 2009-12-02
GB0703966D0 (en) 2007-04-11
KR20090115861A (ko) 2009-11-09
TW200836737A (en) 2008-09-16
AU2008220620A1 (en) 2008-09-04
WO2008104735A1 (en) 2008-09-04
AR065580A1 (es) 2009-06-17
JP5577101B2 (ja) 2014-08-20
PT2125019E (pt) 2014-07-11
BRPI0807902A2 (pt) 2014-06-17
ZA200905689B (en) 2010-10-27

Similar Documents

Publication Publication Date Title
MX2009009131A (es) Mejoras en y con relacion a composiciones medicinales.
MX2009009132A (es) Composiciones medicinales mejoradas que comprenden buprenorfina y naltrexona.
JP2010520186A5 (enExample)
MX2009009133A (es) Composiciones medicinales mejoradas que comprenden buprenorfina y naloxona.
MX2009009134A (es) Composiciones medicinales mejoradas que comprenden buprenorfina y nalmefeno.
JP2010520183A5 (enExample)
NZ605887A (en) Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for the treatment of neuropathic pain
NZ604029A (en) Methods of treating bladder cancer
NZ595467A (en) Sublingual pharmaceutical composition comprising a neutral oil
MX2009002314A (es) Composiciones farmaceuticas que comprenden hgh para suministro oral.
NZ597378A (en) Treatment of multiple sclerosis with laquinimod
IL203747A (en) Use of a steroid sex precursor in the manufacture of a 13mg dose or less for daily dosing through the vagina to treat vaginal diseases and a vaginal pharmacological preparation containing it
WO2008085765A3 (en) Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
MX2010005631A (es) Nuevos compuestos de hidrocarburo ciclicos para el tratamiento de enfermedades.
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
MY173215A (en) Acetylcysteine compositions and methods of use thereof
WO2012007159A3 (en) Novel gastro-retentive dosage forms
IL196425A (en) Dosage unit for oral administration containing ibuprofen and pamotidine
NZ595046A (en) Compositions and methods for extended therapy with aminopyridines
WO2007012019A3 (en) Medicaments containing famotidine and ibuprofen and administration of same
NZ591525A (en) Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin
JP2010520184A5 (enExample)
NZ617397A (en) Pth-containing therapeutic/prophylactic agent for osteoporosis, characterized in that pth is administered once a week at unit dose of 100 to 200 units
WO2008106689A3 (en) Breakthrough pain management
MX2013003523A (es) Composicion farmaceutica de dosis baja.

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: RB PHARMACEUTICALS LIMITED.*

FG Grant or registration